Psoralidin
(Synonyms: 补骨脂定) 目录号 : GC14847
A furanocoumarin with anti-cancer activity
Cas No.:18642-23-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Psoralidin is a dual inhibitor of COX-2 and 5-LOX. Psoralidin, a coumestan derivative isolated from seed of Psoralea corylifolia, has been widely used in traditional medicine for bleeding, pollakiuria, enuresis, vitiligo, and psoriasis. Psoralidin shows a variety of biological activities such as anti-cancer, anti-bacterial, anti-oxidant, anti-depressant activities and regulation of insulin signaling [1].
Psoralidin (100 μM) inhibited COX-2 in IR-irradiated normal lung fibroblasts in HFL-1 and MRC-5 cells [1]. Psoralidin significantly inhibited IR-induced NF-κB-luciferase activity. Psoralidin inhibited the IR-induced COX-2 expression and PGE2 production through regulation of PI3K/Akt and NF-κB pathway. Also, psoralidin blocked IR-induced LTB4 production through direct interaction with 5-lipoxygenase activating protein (FLAP) in 5-LOX pathway. Psoralidin significantly attenuated IR-induced fibroblast migration [1]. Psoralidin inhibited LPS-induced iNOS expression via repressing Syk-mediated activation of PI3K-IKK-IκB signaling pathways [2]. Psoralidin enhanced TRAIL-induced apoptosis in HeLa cells through increased expression of TRAIL-R2 death receptor and depolarization of mitochondrial membrane potential [3].
In male BALB/c strain mice (eight weeks, average weight 22–25 g), psoralidin (5 mg/kg) suppressed IR-induced expression of pro-inflammatory cytokines (TNF-α, TGF-β, IL-6 and IL-1 α/β) and ICAM-1 [1].
References:
[1] Yang H J, Youn H S, Seong K M, et al. Psoralidin, a dual inhibitor of COX-2 and 5-LOX, regulates ionizing radiation (IR)-induced pulmonary inflammation[J]. Biochemical pharmacology, 2011, 82(5): 524-534.
[2] Chiou W F, Don M J, Liao J F, et al. Psoralidin inhibits LPS-induced iNOS expression via repressing Syk-mediated activation of PI3K-IKK-IκB signaling pathways[J]. European journal of pharmacology, 2011, 650(1): 102-109.
[3] Bronikowska J, Szliszka E, Jaworska D, et al. The coumarin psoralidin enhances anticancer effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)[J]. Molecules, 2012, 17(6): 6449-6464.
| Cas No. | 18642-23-4 | SDF | |
| 别名 | 补骨脂定 | ||
| 化学名 | 3,9-dihydroxy-2-(3-methyl-2-buten-1-yl)-6H-benzofuro[3,2-c][1]benzopyran-6-one | ||
| Canonical SMILES | OC1=CC(O2)=C(C=C1)C3=C2C4=C(OC3=O)C=C(O)C(C/C=C(C)/C)=C4 | ||
| 分子式 | C20H16O5 | 分子量 | 336.3 |
| 溶解度 | ≤14mg/ml in DMSO;14mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.9735 mL | 14.8677 mL | 29.7354 mL |
| 5 mM | 0.5947 mL | 2.9735 mL | 5.9471 mL |
| 10 mM | 0.2974 mL | 1.4868 mL | 2.9735 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet